Skip to main content
David Herrmann, MD, Neurology, Rochester, NY, Strong Memorial Hospital of the University of Rochester

DavidNHerrmannMD

Neurology Rochester, NY

Neuromuscular Medicine, Neurophysiology

Professor, Neurology, Chief, Neuromuscular Division, University of Rochester School of Medicine & Dentistry

Dr. Herrmann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Herrmann's full profile

Already have an account?

Education & Training

  • University of Michigan Health System
    University of Michigan Health SystemFellowship, Clinical Neurophysiology, 1998 - 1999
  • University of Michigan Health System
    University of Michigan Health SystemResidency, Neurology, 1995 - 1998
  • University of the Witwatersrand
    University of the WitwatersrandClass of 1989

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1999 - 2024
  • GA State Medical License
    GA State Medical License 2014 - 2015
  • MI State Medical License
    MI State Medical License 1994 - 2001
  • American Board of Psychiatry and Neurology Neurology
  • American Board of Psychiatry and Neurology Clinical Neurophysiology
  • American Board of Psychiatry and Neurology Neuromuscular Medicine

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Peripheral Sensory Pathology Seen in Autism Spectrum Disorder
    Peripheral Sensory Pathology Seen in Autism Spectrum DisorderOctober 15th, 2020
  • CMT1A Patients Needed for Study Seeking New Ways to Monitor Disease Progression
    CMT1A Patients Needed for Study Seeking New Ways to Monitor Disease ProgressionSeptember 15th, 2020
  • Regenacy Pharmaceuticals Announces Collaboration with the Charcot-Marie-Tooth Association (CMTA) to Advance Ricolinostat for the Treatment of Hereditary Neuropathy
    Regenacy Pharmaceuticals Announces Collaboration with the Charcot-Marie-Tooth Association (CMTA) to Advance Ricolinostat for the Treatment of Hereditary NeuropathyAugust 2nd, 2018
  • Join now to see all

Grant Support

  • In-Vivo Confocal Imaging Of Meissner'S Corpuscles As A Measure Of HIV NeuropathyNational Institute Of Neurological Disorders And Stroke2007–2008
  • Epidermal Innervation As An Outcome MeasureNational Institute Of Neurological Disorders And Stroke2002–2006

Hospital Affiliations